Clinical trials: Ovarian Cancer, completed
Ovarian Cancer
Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma
Topotecan and gemcitabine are drugs globally registered for recurrent ovarian carcinoma. This trial will determine the maximum tolerated dose and the efficacy of this combination administered weekly in patients with platinum…
- Trial name
- NCT00429559
- Testing
- Hycamptin, Gemcitabine
- Where
- 6 sites in Greece
- Volunteers
- 31 people
- Sponsor
- Hellenic Oncology Research Group
Ovarian Cancer
Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
Phase II single arm, open label, nonrandomized study. The aim of our study is to assess the Progression Free Survival (PFS) in suboptimally cytoreduced epithelial ovarian/ primary peritoneal/ fallopian tube cancer patients…
- Trial name
- NCT02766582
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Medical College of Wisconsin
Epithelial Ovarian Cancer, Chinese
A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer
The association between homologous recombination (HR) gene mutations and homologous recombination deficiency (HRD) status in Chinese epithelial ovarian cancer (EOC) patients is little known.
- Conditions
- Epithelial Ovarian Cancer, Chinese, Homologous Recombination Deficiency, BRCA1 Mutation
- Trial name
- NCT04651920
- Testing
- Evaluation of homologous recombination deficiency score
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Lei Li
Polycystic Ovary Syndrome
Effects of a Ketogenic Diet on PCOS Outcomes
The aim of the study is to investigate the effects of a low calorie Mediterranean ketogenic diet on Polycystic Ovary Syndrome (PCOS) related outcomes.
- Trial name
- NCT04163120
- Testing
- Low calorie Mediterranean ketogenic diet with phytoextracts (KEMEPHY)
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- University of Padova
Polycystic Ovarian Syndrome (PCOS)
Treatment of Women With Hyperandrogenic PCOS With Two Different Ratios of Myo-inositol:D-chiro-inositol: A Comparison
In this study, female patients diagnosed with polycystic ovary syndrome (PCOS) will be enrolled. In particular, those with elevated testosterone or with clinical signs of hyperandrogenism, along with menstrual cycle alterations…
- Trial name
- NCT06715527
- Testing
- Myo-Inositol and D-Chiro-Inositol (40:1), Myo-Inositol and D-Chiro-Inositol (3.6:1)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Lo.Li.Pharma s.r.l
Fallopian Tube Cancer, Ovarian Cancer
Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy such as carboplatin use different ways to stop tumor cells from dividing so they stop…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00028912
- Testing
- bortezomib, carboplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int
This is a Phase I trial to determine the maximum tolerated dose/maximum feasible dose (MTD/MFD) of a single infusion of FATE-NK100 via intra-peritoneal catheter in women with recurrent ovarian, fallopian tube or primary…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT03213964
- Testing
- FATE-NK100, Interleukin-2
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Ovarian Cancer
A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer
Ovarian cancer is the most lethal gynecological cancer and the 5th leading cause of cancer death in women. Platinum chemotherapy has been widely adopted as a standard treatment for advanced ovarian cancer, the response rates in…
- Trial name
- NCT03989336
- Testing
- Manganese Chloride, nab-paclitaxel, Platinum chemotherapy
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Chinese PLA General Hospital
Polycystic Ovary Syndrome
Research of Intensive Lifestyle Intervention for PCOS Patients With IGT
Compare the efficacy between intensive lifestyle intervention and drugs (GLP-1 Receptor Agonists, metformin and acarbose) for PCOS patients with early onset diabetes in their metabolic and reproductive abnormalities treatment…
- Trial name
- NCT02446834
- Testing
- intensive lifestyle intervention, GLP-1 Receptor Agonists, Metformin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- RenJi Hospital
Solid Tumors
Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
The purpose of this study was to assess the safety of the combination of relacorilant (CORT125134), a novel glucocorticoid receptor (GR) antagonist, and nab- paclitaxel in participants with solid tumors and to determine the…
- Trial name
- NCT02762981
- Testing
- Relacorilant with nab-paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 85 people
- Sponsor
- Corcept Therapeutics
Ovarian Neoplasms, Fallopian Tube Neoplasms
Pharmacogenomics of Paclitaxel in Ovarian Cancer
This study will try to determine whether or not certain genes are responsible for the huge variation in toxicity and effect observed between patients treated with paclitaxel (chemotherapeutic drug).
- Trial name
- NCT00415207
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- University of Southern Denmark
Ovarian Cancer
Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer
The combination of paclitaxel and carboplatin in a three weeks schedule has emerged as the current standard approach for the adjuvant treatment of ovarian cancer.
- Trial name
- NCT00170664
- Testing
- Paclitaxel, Carboplatin
- Where
- Germany
- Volunteers
- 129 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Cancer of Digestive System, Ovarian Cancer
Feasibility Study for Robotic Endomicroscopy to Better Define Resection Strategies (PERSEE)
This study aims at demonstrating the feasibility of probe-based confocal laser endomicroscopy (pCLE) and needle-based confocal laser endomicroscopy (nCLE).
- Trial name
- PERSEE (NCT02312167)
- Testing
- confocal laser endomicroscopy
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Institut Mutualiste Montsouris
Lung Cancer, Adult Soft Tissue Sarcoma
Vaccine Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic…
- Conditions
- Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer
- Trial name
- NCT00020267
- Testing
- interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Polycystic Ovary Syndrome, c Type Natriuretic Peptide
Comparison of Serum C Type Natriuretic Peptide Levels Between Polycystic Ovary Syndrome Patients and Healthy Women
Recent studies have shown that C natriuretic peptide is produced from granulosa cells, increasing cumulative guanosine monophosphate (cGMP) production by affecting cumulus cells through natriuretic peptide receptors.
- Conditions
- Polycystic Ovary Syndrome, c Type Natriuretic Peptide, Menstrual Irregularity, Hyperandrogenism
- Trial name
- CNP (NCT04006171)
- Testing
- C type natriuretic peptide
- Where
- Cyprus
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Near East University, Turkey
Non Small Cell Lung Cancer, Urothelial Carcinoma
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
In this phase I first-in-humans-study a vaccine consisting of arginase-1 (ARG1) peptides and the adjuvant Montanide ISA-51 will be tested in ten patients with metastatic solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Urothelial Carcinoma, Malignant Melanoma, Ovarian Cancer
- Trial name
- NCT03689192
- Testing
- ARG1-18,19,20
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Herlev Hospital
Health and Coping Undergoing Ovarian Cancer Surgery., Cancer Rehabilitation
Health and Coping Prior to Ovarian Cancer Surgery
Background Denmark has a record-high incidence of, and mortality rate for, ovarian cancer. There are 600 new cases of ovarian cancer each year.
- Trial name
- NCT01213771
- Testing
- Preoperative preparation 2010
- Where
- Denmark
- Volunteers
- 279 people
- Sponsor
- University of Aarhus
Ovarian Epithelial Carcinoma
A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression
The purpose of this study is to obtain an estimate of the biochemical response rate as determined by CA125 response using the Gynecologic Cancer Intergroup (GCIG) response criteria of PD0332991 in patients with recurrent ovarian…
- Trial name
- NCT01536743
- Testing
- PD0332991
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Ovary Cancer, Fallopian Tube Cancer
KORE-INNOVATION: a Prospective, Multi-site Clinical Trial to Implement and Analyse the Effects of an Innovative Perioperative Care Pathway to Reduce Complications for Patients with Ovarian Cancer
KORE-INNOVATION is a multi-center clinical study aiming to implement and analyze an innovative care pathway to reduce perioperative complications for patients undergoing surgical treatment for ovarian cancer.
- Conditions
- Ovary Cancer, Fallopian Tube Cancer, Peritoneum Cancer, Frailty
- Trial name
- KORE (NCT05256576)
- Testing
- Implementation of an innovative multi-modal peri-operative care pathway
- Where
- 2 sites in Germany
- Volunteers
- 465 people
- Sponsor
- Charite University, Berlin, Germany
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer
- Trial name
- NCT00007813
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.